[HTML][HTML] Early treatment for Covid-19 with SARS-CoV-2 neutralizing antibody sotrovimab
…, DR Falci, E Sarkis, J Solis, H Zheng… - … England Journal of …, 2021 - Mass Medical Soc
Background Coronavirus disease 2019 (Covid-19) disproportionately results in hospitalization
or death in older patients and those with underlying conditions. Sotrovimab is a pan-…
or death in older patients and those with underlying conditions. Sotrovimab is a pan-…
Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis
…, L Flint, HJF van Hoogstraten, AC Chen, H Zheng… - Gastroenterology, 2014 - Elsevier
Background & Aims The comparative efficacy and safety of infliximab and azathioprine
therapy alone or in combination for ulcerative colitis (UC) have not been evaluated previously. …
therapy alone or in combination for ulcerative colitis (UC) have not been evaluated previously. …
Effect of sotrovimab on hospitalization or death among high-risk patients with mild to moderate COVID-19: a randomized clinical trial
…, J Moya, DR Falci, E Sarkis, J Solis, H Zheng… - Jama, 2022 - jamanetwork.com
Importance Older patients and those with comorbidities who are infected with SARS-CoV-2
may be at increased risk of hospitalization and death. Sotrovimab is a neutralizing antibody …
may be at increased risk of hospitalization and death. Sotrovimab is a neutralizing antibody …
High sustained virologic response rates in children with chronic hepatitis C receiving peginterferon alfa-2b plus ribavirin
…, B Hunter, Z Goodman, CR Xu, H Zheng… - Journal of …, 2010 - Elsevier
BACKGROUND & AIMS: Pegylated interferon (PEG-IFN) alfa-2b plus ribavirin (RBV) is the
standard of care for adults with chronic hepatitis C but was not approved for the treatment of …
standard of care for adults with chronic hepatitis C but was not approved for the treatment of …
Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: results from the phase 3 randomized OPERA I, OPERA II, and …
Background Ocrelizumab is an infusible humanized monoclonal antibody that selectively
depletes CD20 + B cells. Infusion-related reactions (IRRs) were summarized from the OPERA I, …
depletes CD20 + B cells. Infusion-related reactions (IRRs) were summarized from the OPERA I, …
Effect of the neutralizing SARS-CoV-2 antibody sotrovimab in preventing progression of COVID-19: a randomized clinical trial
…, J Moya, DR Falci, E Sarkis, J Solis, H Zheng… - medRxiv, 2021 - medrxiv.org
Importance Older patients and those with underlying comorbidities infected with SARS-CoV-2
may be at increased risk of hospitalization and death from COVID-19. Sotrovimab is a …
may be at increased risk of hospitalization and death from COVID-19. Sotrovimab is a …
Atezolizumab in platinum-treated locally advanced or metastatic urothelial carcinoma: clinical experience from an expanded access study in the United States
SK Pal, J Hoffman-Censits, H Zheng, C Kaiser… - European Urology, 2018 - Elsevier
Background Atezolizumab (anti–programmed death-ligand 1) was approved in the USA,
Europe, and elsewhere for treatment-naive and platinum-treated locally advanced/metastatic …
Europe, and elsewhere for treatment-naive and platinum-treated locally advanced/metastatic …
Early Covid-19 Treatment With SARS-CoV-2 Neutralizing Antibody Sotrovimab (preprint)
…, J Moya, DR Falci, E Sarkis, J Solis, H Zheng… - 2021 - pesquisa.bvsalud.org
Background: Coronavirus disease 2019 (Covid-19) disproportionately results in hospitalization
and death in older patients and those with underlying comorbidities. Sotrovimab is a pan-…
and death in older patients and those with underlying comorbidities. Sotrovimab is a pan-…
Impact of ocrelizumab on cognition in patients at increased risk of progressive disease (P1. 420)
Objective: To determine the impact of ocrelizumab vs interferon (IFN) β-1a on cognition
using the Symbol Digit Modalities Test (SDMT) in patients with relapsing multiple sclerosis (RMS) …
using the Symbol Digit Modalities Test (SDMT) in patients with relapsing multiple sclerosis (RMS) …
Interim analysis of the OBOE (Ocrelizumab Biomarker Outcome Evaluation) study in multiple sclerosis (MS)(S24. 002)
…, D Fiore, C Harp, X Ma, A Herman, B Musch, H Zheng… - 2018 - AAN Enterprises
… Zheng has received personal compensation for consulting, serving on a scientific advisory
board, speaking, or other activities with Compensation from Genentech and stock in F. …
board, speaking, or other activities with Compensation from Genentech and stock in F. …
